NCT06201559View on ClinicalTrials.gov

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions
Intestinal Diseases
Interventions
DRUG

Albendazole IP 400 mg

Albendazole IP 400 mg tablets will be administered under fed conditions

DRUG

Albendazole 400 mg

Albendazole 400 mg tablets will be administered under fed conditions

Trial Locations (1)

382481

GSK Investigational Site, Ahmedabad

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06201559 - Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions | Biotech Hunter | Biotech Hunter